Finch Therapeutics, based in Somerville, MA, is a pioneering company in the field of microbiome therapeutics, with a robust intellectual property estate and a portfolio of innovative microbiome assets. They have recently made the decision to discontinue their Phase 3 trial of CP101 in recurrent C. difficile and focus on realizing the value of their IP estate and other assets.
With insights from human microbiota transplantation studies, Finch has established a leading portfolio of microbiome assets that have potential applicability to a wide range of product strategies and therapeutic areas. They are dedicated to advancing the field of microbiome therapeutics and exploring partnership opportunities to further their mission.
Generated from the website